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INTRODUCTION
Renal cell carcinoma (RCC) is the most common
malignant tumor that arises from the kidney. Five-
year survival rates for patients with tumors confined
to the kidney range from 60% to 90% (1, 2). Once
RCC has metastasized, the 5-year survival rate is
less than 10% (3). The main prognostic indicator in
RCC patients is clinical stage, and the presence or
absence of metastasis at the time of diagnosis re-
mains the main factor in determining survival (4).
Tumor nuclear grade and histologic features such as
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cell type carry only limited prognostic value (5, 6).
Consequently, a need exists for additional diagnos-
tic and prognostic markers to identify the activity
of RCC.
Recent studies show that angiogenesis plays an
important role in the growth, progression, and me-
tastasis of solid tumors (7). Several factors have
been identified which enhance angiogenesis, such
as basic fibroblast growth factor (b-FGF) and vas-
cular endothelial growth factor (VEGF) (8, 9). In-
creased circulating levels of b-FGF and VEGF have
been reported in renal cell carcinoma patients (10,
11). More recently, many observations have indi-
cated that hepatocyte growth factor (HGF) is also
a powerful inducer of angiogenesis (12, 13).
HGF is a stromal cell-derived cytokine involved in
cell proliferation, tissue regeneration, tumor growth
and tumor invasion (14-17). The role of HGF in tu-
mor biology has been supported by immunohisto-
chemical studies in various human carcinomas, in-
cluding RCC (18, 19). Recent studies have shown
that HGF and its receptor, c-MET, play a significant
role in the progression of RCC (20, 21). Positive cor-
relation between HGF/Met expression levels of
RCC tissue and tumor progression has been shown
(20, 21). To our knowledge, there exists a lack of
quantitative data comparing the serum concentra-
tion of HGF to clinicopathological findings and clini-
cal outcome in RCC patients.
In the present report, we examined the serum
levels of HGF and VEGF, which are strong angio-
genic factors, in 45 patients with clear cell RCC and
45 healthy individuals, using an enzyme-linked im-
munosorbent assay (ELISA). We investigated the
correlation of serum HGF levels with clinicopa-
thological parameters and compared the diagnostic
and prognostic value of serum HGF with serum
VEGF in clear cell RCC patients.
MATERIALS AND METHODS
We analyzed pretreatment serum HGF and VEGF
concentrations from 45 patients with clear cell RCC
admitted to the Department of Urology, The Uni-
versity Hospital of Tokushima School of Medicine,
Japan. Of these patients, 27 were male and 18 were
female with a mean age of 61.5 years (range 23 to
81 years). Patients with a renal tumor that was his-
tologically different from clear cell RCC were ex-
cluded because a phenotype of RCC was quite dif-
ferent based on the histological subtypes. Moreover,
we excluded the patients with evidence of other
cancer, recent trauma or surgery, pregnancy, and
hepatitis to avoid the possibility of elevated serum
HGF and VEGF concentrations. The serum samples
were collected before nephrectomy or other treat-
ments such as chemotherapy or interferon and/or
interleukin-2 (IL-2) immunotherapy. Tumors were
staged according to the TNM staging classification
of the International Union Against Cancer (22).
Staging procedures included physical examination,
chest radiography, ultrasonography, and comput-
erized tomography. If caval invasion was suspected,
magnetic resonant scanning was performed. Pa-
tients with elevated serum alkaline phosphates or
skeletal symptoms were assessed by bone scintig-
raphy and radiography. As shown in Table 1, the pa-
tients were staged as follows : 11 stage I, 18 stage
II, 5 stage III, and 11 stage IV. Twenty-nine pa-
tients had low stage cancer (stage I and II), and 16
patients had high stage cancer (stage III and IV).
Tumor nuclear grading was performed according
to the 1997 TNM grading system (22). The grade
distribution was as follows : 14 grade 1, 26 grade 2,
and five grade 3 tumors. Follow-up ranged 4.9 to
109.0 months (average 38.6 months).
Informed consent was obtained from all the sub-
jects, and the study protocol was approved by the
ethics committee.
Table 1 Summary of the characteristics of 45 patients with
clear cell renal cell carcinoma
Characters No. of patients
Age
23-81 yrs (mean, 61.5 yrs)
Sex
Male 27
Female 18
Clinical stage
I 11
II 18
III 5
IV 11
Histologic grade (G)
G1 14
G2 26
G3 5
Follow-up period
4.9-109.0 mos (median, 38.6 mos)
The Journal of Medical Investigation Vol. 55 February 2008 107
Controls
Blood samples were obtained from the peripheral
veins of 45 subjects with no evidence of disease,
such as inflammatory disease or other cancers. The
subjects included 32 men and 13 women with a
mean age of 48.2 years (range 23 to 84 years). The
absence of disease was assessed by clinical exami-
nation and routine laboratory tests.
HGF and VEGF analysis
Prior to treatment, a 10 mL clotted blood sam-
ple was taken, centrifused at 2000 rpm for 10 min-
utes and a 1 mL aliquot of serum was then stored
at -80until analysis. The serum levels of HGF
and VEGF were measured using sandwich enzyme
immunoassay methods (Quantikine, R&D systems,
Minneapolis, MN). We tested each samples at least
in duplicate and repeated an experiment three times.
Statistical analysis
Distribution of serum HGF between different
groups was compared using the Mann-Whitney-U
test. Survival curves were estimated using the Kaplan-
Meier method, and survival times were compared
by the log-rank test. Survival time was measured
from date of diagnosis to date of death or last follow-
up. Sensitivity and specificity were calculated from
the receiver-operating-characteristics (ROC) curve.
Statistical significance was concluded based on p
0.05 as a minimum level.
RESULTS
Serum HGF concentrations ranged from 416.7
to 1037.3 pg/ml (median 728.3 pg/ml), and serum
VEGF concentrations ranged from 11.3 to 921.7 pg/
ml (median 245.6 pg/ml) in the presumably healthy
individuals (Table 2). There was no difference in
gender between RCC group and healthy controls,
but patients with clear cell RCC was older than
health individuals (data not shown). However, there
is no significant correlation in serum HGF and VEGF
levels with gender and age.
A significant correlation was found between
absolute HGF and VEGF serum levels (n=45 ; r=
0.570 ; p0.001) (Fig. 1). HGF and VEGF blood
levels were significantly higher in the 45 patients
with RCC than in the 45 healthy controls (HGF,
median 1070.7 in RCC patients versus 728.3 pg/ml
in healthy controls, p0.0001 ; VEGF, median 397.5
in RCC patients versus 245.6 pg/ml in healthy con-
trols, p=0.0003). Serum HGF levels were signifi-
cantly higher in patients with high stage RCC than
in those with low stage cancer (median 1252.9 ver-
sus 948.7 pg/ml, p=0.0044), in patients with high
grade (grade 2 and 3) cancer than in those with
grade 1 cancer (median 1163.4 versus 845.8 pg/ml,
p=0.0419), in patients with distant metastasis than
in those without distant metastasis (median 1375.0
versus 836.6 pg/ml, p=0.0014). No significant dif-
ferences were observed between serum VEGF lev-
els and stage (median 397.5 for low stage versus
Table 2 Levels of serum HGF in healthy controls and patients with clear cell renal cell carcinoma
HGF (pg/ml) VEGF (pg/ml)
Group No. of patients Median Range P value Median Range P value
Healthy individuals 45 728.3 416.7-1037.3 p0.0001a 245.6 11.3-921.7 p=0.0003 a
Clear cell renal cancer 45 1070.7 412.6-2572.0 397.5 99.3-1256.3
Low stage (I+II) 29 948.7 453.6-1539.0 p=0.0044b 397.5 113.2-984.7 p=0.7579
High stage (III+IV) 16 1252.9 412.6-2572.0 383.4 99.3-1256.3
Non-Metastatic (M0) 34 836.6 453.6-1539.0 p=0.0014c 293.7 113.2-984.7 p=0.061
Metastatic (M1) 11 1375.0 412.6-2572.0 412.1 99.3-1256.3
Low grade (G1) 14 845.8 453.6-1200.5 p=0.0419d 290.0 113.2-500.0 p=0.0607
High grade (G2+3) 31 1163.4 412.6-2572.0 412.1 99.3-1256.3
a P value refers to the difference between the healthy controls and all patients with clear cell renal cancer.
b, c, d P values refer to the difference between the patients with low stage and high stage RCC or between the patients with distant
metastasis and without distant metastasis, or between the patients with low grade and high grade RCC.
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383.4 pg/ml for high stage, p=0.7579) or between
serum VEGF levels and nuclear grade (median
290.0 for low grade versus 412.1 pg/ml for high
grade, p=0.0607) (Table 2). There was no difference
between serum HGF and VEGF levels and tumor
size (data not shown).
Patients with low stage RCC survived signifi-
cantly longer than patients with high stage RCC
(p=0.0008) (data not shown). Survival time of pa-
tients with high nuclear grade was significantly
shorter than for those with low nuclear grade RCC
(p0.05) (data not shown). Cutoff values of HGF
and VEGF defined by ROC analysis were 1150 pg/
ml and 400 pg/ml, respectively. The serum HGF
cutoff value was most effective for differentiating
the survival of patients in the current study. The
sensitivity and specificity of serum HGF at the cut-
off level of 1150 pg/ml were 85.7% and 57.8%, re-
spectively, and of serum VEGF at the cutoff level of
400 pg/ml, 85.7% and 46.7%, respectively. Patients
with serum HGF levels above the cutoff values ex-
hibited significantly reduced survival compared
to patients with lower values (p=0.0044) (Fig. 2). No
significant difference was observed between serum
VEGF level and cause-specific survival rate (data
not shown).
In patients with the grade 2 RCC, six of 12 pa-
tients in the higher serum HGF subgroup (1150
pg/ml) died of RCC, whereas only one of 14 pa-
tients in the lower serum HGF subgroup (1150
pg/ml) died of RCC. Figure 3A shows that the
higher serum HGF subgroup in patients with grade
2 RCC exhibited significantly lower cause-specific
survival (p=0.0087). Figure 3B indicates that in the
cases with high stage tumors (stage III and IV), the
higher serum HGF subgroup also had significantly
lower cause-specific survival (p0.05). No significant
differences were observed between serum VEGF
levels and cause-specific survival rate in grade 2
Fig. 2 Kaplan-Meier cause-specific survival curves according
to serum levels of HGF.
A
B
Fig. 3 Kaplan-Meier cause-specific survival curves according
to serum levels of HGF in patients with grade 2 tumors (A) and
with high stage (stage III and IV) tumors (B).
Fig. 1 Correlation of serum HGF and VEGF levels in 45 pa-
tients with clear cell renal cell carcinoma. Each dot represents
the HGF and VEGF serum level of one patient (simple linear
regression : r=0.570 ; p0.001).
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RCC (p=0.4906) or in high stage RCC (p=0.2278)
(data not shown). There was no significant corre-
lation between serum HGF levels and cause-specific
survival rate in patients with grade 1 and grade 3
RCC.
DISCUSSION AND CONCLUSIONS
RCC is characterized by a lack of early warning
signs, resulting in a high proportion of patients with
metastasis at diagnosis or relapse following nephrec-
tomy. RCC is also known for its unpredictable clini-
cal behavior. Progression of metastasis can occur
many years after surgery on the primary tumor, or
spontaneous regression of distant metastasis is ob-
served (23, 24). A need exists for prognostic fac-
tors that identify the subsets of RCC patients with
low versus high risk at the time of diagnosis. Re-
cently, it has been suggested that one of the angio-
genic factors, hepatocyte growth factor (HGF), plays
an important role in tumor progression and angio-
genesis of RCC (18, 20, 21). Several studies have
implicated the involvement of HGF and its recep-
tor MET signaling in the oncogenesis of RCC (18,
20, 21). Nevertheless, the biological significance of
serum HGF levels has not yet been fully clarified.
In the current study, we observed higher concen-
trations of serum HGF and VEGF in patients with
cancer than individuals without RCC. Importantly,
only serum HGF levels of high stage RCC patients
were significantly higher than in low stage RCC
patients. These results suggest that serum HGF is
more useful as a diagnostic marker for screening
of RCC than serum VEGF. Dosquet, et al. reported
that serum HGF levels of nonmetastatic RCC pa-
tients was significantly higher than that of controls,
but they found no correlation between serum HGF
levels and tumor stage (10). In our study, serum
HGF level increased with more advanced clinical
stage and with higher nuclear grade. It was sug-
gested that our exclusion of patients with potentially
elevated serum HGF concentration due to other con-
ditions diminished any sampling error.
Our recent results showed that serum HGF and
VEGF levels were directly correlated with progno-
sis of clear cell RCC patients. Although it is danger-
ous to use arbitrary cutoffs to determine signifi-
cance, a cutoff value of serum HGF (1150 pg/ml)
and VEGF (300 pg/ml) defined by ROC analysis
effectively differentiated the survival of the patients.
Our data showed that both the higher serum HGF
and VEGF subgroups had a significantly lower sur-
vival. In multivariate analysis, we found that both
serum HGF and VEGF lost its prognostic informa-
tion. A similar observation was noted in VEGF for
RCC (11). This might depend on the sample num-
bers, follow-up periods, and the methods used for
the analysis of HGF and VEGF expression. Prospec-
tive studies involving larger numbers of patients and
longer follow-up periods are needed to confirm these
findings.
In this study, we found the prognostic significance
of serum HGF levels among patients with grade 2
RCC. It is difficult to evaluate the biological aggres-
siveness of grade 2 tumors because grade 2 RCC re-
mains heterogeneous. Therefore, it is important to
differentiate high and low risk groups in the grade
2 RCC patients. Our results showed that the higher
serum HGF group had significantly worse cause-
specific survival in grade 2 RCC patients, though
serum VEGF levels and tumor stage can not pre-
dict prognosis. Furthermore, in high stage tumors
(stages III and IV), the higher serum HGF group
also had significantly worse cause-specific survival.
Serum HGF levels, but not VEGF levels can clini-
cally differentiate patients with the grade 2 and high
stage RCC into high and low risk, and is significantly
correlated with prognosis and survival.
In conclusion, Serum HGF levels significantly cor-
related with tumor stage, histological grade, and
prognosis of RCC. Our results indicate that serum
levels of HGF can be useful as a diagnostic and
prognostic marker for patients with untreated clear
cell RCC. Although serum HGF did not remain an
independent prognostic factor in multivariate analy-
sis, serum HGF levels might be useful for the identi-
fication of patients with potentially progressive dis-
ease, especially for those with grade 2 and/or high
stage RCC. Serum HGF may enhance the accuracy
of conventional morphologic grading and pathologic
staging systems in RCC patients. In this series, we
evaluated pretreatment serum HGF concentrations
in patients with clear cell RCC. In the future, it will
be necessary to evaluate the post-therapeutic prog-
nostic accuracy of serum HGF levels for therapy
monitoring.
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